Current News

Contact | Print version | PDF version | Send article | RSS feed

Selvita becomes the strategic investor in BioCentrum

31 Mar 2008 - Selvita and BioCentrum have entered into a strategic cooperation agreement. As part of the agreement BioCentrum will become a part of Selvita group and will concentrate the potential of both companies in the area of ADMET contract research, including microbiology and biochemistry assays and the development and production of proteins. Selvita will continue to develop its innovative compound pipeline as well as offer advanced services to the drug industry including drug discovery and design, bioinformatics and chemical informatics.
 
"The cooperation with Selvita will help us to develop our service offerings, increase research and marketing budgets and increase and improve BioCentrum's laboratory infrastructure", said Prof. Adam Dubin, the founder and former CEO of BioCentrum. "In four years since the company was founded our company has gained a good reputation in the international biotechnology community. Based on our cooperation with the Biochemistry, Biophysics and Biotechnology Department of the Jagiellonian University we developed unique research capabilities and now it is time to reach out for new customers".
 
Selvita acquired 64% of shares of BioCentrum after the capital increase. Pawel Przewiezlikowski, the CEO of Selvita will become also the CEO of BioCentrum, and Boguslaw Sieczkowski, Selvita's Vice President and board member will become a member of the management board of BioCentrum. Professor Adam Dubin, will remain a board member of the company and will assist Selvita in its own research projects. He will assume the role of the President of Selvita's Scientific Advisory Board which includes seven eminent biomedical research scientists.